Cited 255 times in
Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤상선 | - |
dc.date.accessioned | 2016-05-16T11:31:25Z | - |
dc.date.available | 2016-05-16T11:31:25Z | - |
dc.date.issued | 2002 | - |
dc.identifier.issn | 0169-409X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/144739 | - |
dc.description.abstract | Recent evidence indicates that Pseudomonas aeruginosa residing as biofilms in airway mucus of cystic fibrosis (CF) patients is undergoing anaerobic metabolism, a form of growth requiring gene products that are not utilized during aerobic growth. The outer membrane protein, OprF, and the rhl quorum sensing circuit are two previously unrecognized cellular factors that are required for optimal anaerobic biofilm viability. Without OprF, bacteria grow extremely poorly because they lack nitrite reductase activity while lacking rhlR or rhlI forces bacteria to undergo metabolic suicide by overproduction of nitric oxide. Furthermore, anaerobic growth favors maintenance of the mucoid, alginate-overproducing phenotype. Thus, with increasing age of CF patients, mucoid populations predominate, indicating that anaerobic bacteria reside in the inspissated airway mucus. Because many frontline antibiotics used in the treatment of CF airway disease are either ineffective or show reduced efficacy during anaerobic conditions, we propose development of new drugs to combat anaerobic metabolism by P. aeruginosa for more effective treatment of chronic CF lung infections. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1425~1443 | - |
dc.relation.isPartOf | ADVANCED DRUG DELIVERY REVIEWS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Alginates/metabolism | - |
dc.subject.MESH | Anaerobiosis | - |
dc.subject.MESH | Anti-Bacterial Agents/therapeutic use* | - |
dc.subject.MESH | Bacterial Proteins/genetics | - |
dc.subject.MESH | Bacterial Proteins/metabolism | - |
dc.subject.MESH | Biofilms/growth & development* | - |
dc.subject.MESH | Chronic Disease | - |
dc.subject.MESH | Cystic Fibrosis/microbiology* | - |
dc.subject.MESH | Glucuronic Acid | - |
dc.subject.MESH | Hexuronic Acids | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ligases | - |
dc.subject.MESH | Mucus/microbiology | - |
dc.subject.MESH | Nitric Oxide/metabolism | - |
dc.subject.MESH | Porins/metabolism | - |
dc.subject.MESH | Pseudomonas Infections/drug therapy* | - |
dc.subject.MESH | Pseudomonas Infections/microbiology | - |
dc.subject.MESH | Pseudomonas aeruginosa/drug effects | - |
dc.subject.MESH | Pseudomonas aeruginosa/metabolism* | - |
dc.subject.MESH | Pseudomonas aeruginosa/physiology | - |
dc.subject.MESH | Respiratory System/microbiology* | - |
dc.subject.MESH | Transcription Factors/metabolism | - |
dc.title | Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학) | - |
dc.contributor.googleauthor | Daniel J. Hassett | - |
dc.contributor.googleauthor | John Cuppoletti | - |
dc.contributor.googleauthor | Bruce Trapnell | - |
dc.contributor.googleauthor | Sergei V. Lymar | - |
dc.contributor.googleauthor | John J. Rowe | - |
dc.contributor.googleauthor | Sang Sun Yoon | - |
dc.contributor.googleauthor | George M. Hilliard | - |
dc.contributor.googleauthor | Kislay Parvatiyar | - |
dc.contributor.googleauthor | Moneesha C. Kamani | - |
dc.contributor.googleauthor | Daniel J. Wozniak | - |
dc.contributor.googleauthor | Sung-Hei Hwang | - |
dc.contributor.googleauthor | Timothy R. McDermott | - |
dc.contributor.googleauthor | Urs A. Ochsner | - |
dc.identifier.doi | 10.1016/S0169-409X(02)00152-7 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02558 | - |
dc.relation.journalcode | J00040 | - |
dc.identifier.eissn | 1872-8294 | - |
dc.identifier.pmid | 12458153 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169409X02001527 | - |
dc.subject.keyword | Pseudomonas aeruginosa | - |
dc.subject.keyword | Anaerobic growth | - |
dc.subject.keyword | Cystic fibrosis | - |
dc.contributor.alternativeName | Yoon, Sang Sun | - |
dc.contributor.affiliatedAuthor | Yoon, Sang Sun | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 54 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1425 | - |
dc.citation.endPage | 1443 | - |
dc.identifier.bibliographicCitation | ADVANCED DRUG DELIVERY REVIEWS, Vol.54(11) : 1425-1443, 2002 | - |
dc.identifier.rimsid | 51871 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.